All In Biotech

NDA 018960 · Hospira

Cupric Chloride In Plastic Container

Cupric Chloride · Injection

Priority review

Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Jun 26, 1986

Approved uses

1

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

748

502 serious, 42 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 18, 2026.

INDICATIONS AND USAGE Copper (Cupric Chloride Injection) is indicated for use as a supplement to intravenous solutions given for TPN. Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 26, 1986 Original approval · Type 5 - New Formulation or New Manufacturer · priority review
1 products under this application
  • CUPRIC CHLORIDE IN PLASTIC CONTAINER · CUPRIC CHLORIDE EQ 0.4MG COPPER/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Cupric Chloride" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue75
  • off label use74
  • headache64
  • nausea64
  • pain61
  • diarrhoea60
  • drug ineffective53
  • weight decreased49
  • malaise43
  • abdominal pain40
  • anaemia37
  • dizziness36

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20054
20061
20073
20084
20096
20109
201114
201213
201321
201421
201532
201660
201723
201846
201957
202052
202165
202270
202366
202464
202569
202647

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.